Thomas Jefferson University

Saint Joseph's University

Jean-Francois Jasmin

Michael P Lisanti

Kevin Quann

Isabelle Mercier

Shannon Chilewski

The present-disclosure provides methods of treating cancer with certain co-activator of activator protein-1 and estrogen receptor (CAPER)-based polypeptides. In certain embodiments, the methods of the-disclosure target only cancerous cells without adversely affecting non-cancerous cells.

Polypeptides for treatment of cancer

This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject's glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject's glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject's glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide.

Growing community of inventors

Philadelphia, PA, United States of America

Jean-Francois Jasmin